Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
58.78 USD +0.50% Intraday chart for Apellis Pharmaceuticals, Inc. +3.83% -1.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing MT
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing MT
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing MT
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024 CI
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating MT
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:00 AM
Transcript : Apellis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-03-2024 through Mar-06-2024
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating MT
Wedbush Raises Apellis Pharmaceuticals' PT to $67 From $60, Keeps Neutral Rating; Says Awaiting Further Clarity on Potential EU Regulatory Path for Syfovre MT
Transcript : Apellis Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures Pause as Investors Eye Inflation Data DJ
Mizuho Raises PT on Apellis Pharmaceuticals to $60 From $49 Ahead of Q4 2023 Earnings Announcement, Keeps Neutral Rating MT
UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating MT
North American Morning Briefing : Rate Doubts Keep -2- DJ
Jefferies Upgrades Apellis Pharmaceuticals to Buy From Hold, Adjusts Price Target to $80 From $68 MT
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee MT
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $79 From $75, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Chart Apellis Pharmaceuticals, Inc.
More charts
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
58.78 USD
Average target price
82.69 USD
Spread / Average Target
+40.67%
Consensus
  1. Stock
  2. Equities
  3. Stock Apellis Pharmaceuticals, Inc. - Nasdaq
  4. News Apellis Pharmaceuticals, Inc.
  5. Wedbush Lifts Price Target on Apellis Pharmaceuticals to $45 From $42, Maintains Neutral Rating